miR-671 is encoded by a gene on 7q36.1 and contributes to the pathogenesis of a variety of disorders, including diverse types of cancers, atherosclerosis, ischemic stroke, liver fibrosis, osteoarthritis, Parkinson's disease, rheumatoid arthritis, acute myocardial infarction and Crohn's disease. In the context of cancer, different studies have revealed opposite roles for this miRNA. In brief, it has been shown to be down-regulated in pancreatic ductal carcinoma, ovarian cancer, gastric cancer, osteosarcoma, esophageal squamous cell carcinoma and myelodysplastic syndromes. Yet, miR-671 has been up-regulated in glioma, colorectal cancer, prostate cancer and hepatocellular carcinoma. Studies in breast, lung and renal cell carcinoma have reported inconsistent results. The current review aims at summarization of the role of miR-671 in these disorders focusing on its target mRNA in each context and dysregulated signaling pathways. We also provide a summary of the role of this miRNA as a prognostic factor in malignancies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760869 | PMC |
| http://dx.doi.org/10.3389/fmolb.2022.1077968 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sevoflurane Alleviates Myocardial Ischemia/Reperfusion Injury by Targeting the circ_CDR1as/miR-671-5p/HMGA1 Axis.
J Biochem Mol Toxicol
January 2025
Intensive Care Unit, The Third Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Sevoflurane (Sev) has a cardioprotective role in myocardial ischemia/reperfusion injury (MI/RI), but its mechanism has not been fully elucidated. This study aimed to investigate whether the circ_CDR1as/miR-671-5p/HMGA1 axis mediates the cardioprotective effect of Sev in MI/RI. Cardiomyocytes underwent hypoxia/reoxygenation (H/R) treatment was used to simulate MI/RI in vitro.
View Article and Find Full Text PDFSmall-RNA sequencing reveals potential serum biomarkers for gallbladder cancer: Results from a three-stage collaborative study of large European prospective cohorts.
Eur J Cancer
January 2025
Statistical Genetics Research Group, Institute of Medical Biometry, Heidelberg University, Heidelberg, Germany; Laboratory of Biostatistics for Precision Oncology, Institut de Cancérologie Strasbourg Europe, France. Electronic address:
Gallbladder cancer (GBC) is an aggressive disease with limited treatment options but high prevention potential. GBC tumours take 10-20 years to develop, a timeframe that holds potential for early detection. MicroRNAs (miRNAs) play a central role in abnormal cell processes, and circulating miRNAs may constitute valuable biomarkers of early disease.
View Article and Find Full Text PDFMicroRNA Profiling as a Predictive Indicator for Time to First Treatment in Chronic Lymphocytic Leukemia: Insights from the O-CLL1 Prospective Study.
Noncoding RNA
August 2024
Molecular Pathology Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.
A "watch and wait" strategy, delaying treatment until active disease manifests, is adopted for most CLL cases; however, prognostic models incorporating biomarkers have shown to be useful to predict treatment requirement. In our prospective O-CLL1 study including 224 patients, we investigated the predictive role of 513 microRNAs (miRNAs) on time to first treatment (TTFT). In the context of this study, six well-established variables (i.
View Article and Find Full Text PDFCirc_0001947 encapsulated by small extracellular vesicles promotes gastric cancer progression and anti-PD-1 resistance by modulating CD8 T cell exhaustion.
J Nanobiotechnology
September 2024
The Third Department of Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, China.
Article Synopsis
- Scientists found that a special type of small circular RNA called circ_0001947, which comes from gastric cancer cells, can make cancer worse and reduce the body’s immune response against the cancer.
- They used different experiments to see how this circRNA affects cancer cells and immune cells, discovering that it helps cancer cells grow and move around by affecting other molecules in the body.
- The study suggests that targeting this circRNA might help improve treatments for gastric cancer by boosting the immune system's ability to fight the cancer.
Circulating exosomal circRNA-miRNA-mRNA network in a familial partial lipodystrophy type 3 family with a novel frameshift mutation c.418dup.
Am J Physiol Endocrinol Metab
September 2024
Key Laboratory of Endocrinology of National Health Commission, Diabetes Research Center of Chinese Academy of Medical Sciences, Department of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
Article Synopsis
- Familial partial lipodystrophy 3 (FPLD3) is a rare genetic disorder caused by mutations affecting the PPARγ protein, leading to loss of subcutaneous fat and metabolic issues.
- A study on a 17-year-old Chinese girl with FPLD3 identified a new mutation that truncates the PPARγ protein and found that various circRNAs, miRNAs, and mRNAs are significantly altered in mutation carriers compared to healthy controls.
- The research highlights the role of circ_0001597 and miR-671-5p in regulating genes linked to glucose and lipid metabolism, suggesting potential biomarkers and new treatment options for FPLD3.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!